Abstract: The present disclosure provides morphic forms of Compound No. 1: solvates thereof, hydrates thereof, and pharmaceutically acceptable salts thereof. The present disclosure also provides processes for preparing the morphic forms and uses of the morphic forms, e.g., in preventing or treating cancer.

Abstract: According to an aspect, a computer-implemented method includes accessing a profile of a user that indicates a likelihood that the user will execute each of a plurality of types of processing when training a new AI model. A runtime matrix that includes identifiers of runtime environments is accessed. The matrix also includes, for each of the runtime environments, a frequency of use of the runtime environment to train previously trained AI models using each of the plurality of types of processing. One or more of the runtime environments is selected for output to the user based at least in part on the profile of the user and the runtime matrix. Identifiers of the selected one or more of the runtime environments are output to a user interface of the user along with a suggestion to use one of the selected one or more of the runtime environments.

Abstract: A method of operating a shared computing environment includes receiving a client request for an optimized runtime configuration of the shared computing environment for executing a task, receiving runtime data of the task collected from a prior runtime, inferring a runtime configuration from the runtime data, determining a predicted timeseries workload for the shared computing environment, updating the runtime configuration to including the timeseries workload prediction, wherein the updating outputs the optimized runtime configuration, and configuring the shared computing environment according to the optimized runtime configuration in executing the task.

Abstract: A method of operating a shared computing environment includes receiving a client request for an optimized runtime configuration of the shared computing environment for executing a task, receiving runtime data of the task collected from a prior runtime, inferring a runtime configuration from the runtime data, determining a predicted timeseries workload for the shared computing environment, updating the runtime configuration to including the timeseries workload prediction, wherein the updating outputs the optimized runtime configuration, and configuring the shared computing environment according to the optimized runtime configuration in executing the task.

Abstract: Systems and methods for computer-automated labeling of data are disclosed. In embodiments, a method includes: identifying technical data assets in lineage data and corresponding business items in User Interface (UI) data of a user, wherein the lineage data includes a data source for the UI data; mapping the technical data assets to the corresponding business items; determining relevant labels to assign to the technical data assets from a label repository based on a similarity analysis of names of the corresponding business items and labels in the label repository; determining that one or more of the relevant labels meet a confidence threshold based on the similarity analysis; and automatically assigning the one or more of the relevant labels to associated ones of the technical data assets based on the determining that the one or more of the relevant labels meet the confidence threshold.

Abstract: The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula (1), and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula (1) described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula (1) and compositions comprising the crystalline forms of the compound of Structural Formula (1) provided herein, in particular, crystalline Form A, crystalline Form B, crystalline Form C, and crystalline Form D, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms A, B, C and D) of the bis-HCl salt of a compound represented by Structural Formula (1).

Abstract: A computer-implemented method, system and computer program product for identifying an appropriate contact across collaborative applications. Contact information is collected from monitored messages, communication lists and contact lists in each collaborative application. Contact records are generated based on the collected contact information, where such records are inserted into a contact list. After receiving a query from a user containing a keyword(s) that include a nickname (or portion thereof) of a second user whom the user desires to interact via the current collaborative application, a search is performed in the contact list for any record containing a nickname that is similar to the provided keyword(s). Record(s) in the contact list containing a nickname that exceeds a threshold degree of similarity as the keyword(s) are identified.

Abstract: Systems and methods for computer-automated labeling of data are disclosed. In embodiments, a method includes: identifying technical data assets in lineage data and corresponding business items in User Interface (UI) data of a user, wherein the lineage data includes a data source for the UI data; mapping the technical data assets to the corresponding business items; determining relevant labels to assign to the technical data assets from a label repository based on a similarity analysis of names of the corresponding business items and labels in the label repository; determining that one or more of the relevant labels meet a confidence threshold based on the similarity analysis; and automatically assigning the one or more of the relevant labels to associated ones of the technical data assets based on the determining that the one or more of the relevant labels meet the confidence threshold.

Abstract: A computer-implemented method, system and computer program product for identifying an appropriate contact across collaborative applications. Contact information is collected from monitored messages, communication lists and contact lists in each collaborative application. Contact records are generated based on the collected contact information, where such records are inserted into a contact list. After receiving a query from a user containing a keyword(s) that include a nickname (or portion thereof) of a second user whom the user desires to interact via the current collaborative application, a search is performed in the contact list for any record containing a nickname that is similar to the provided keyword(s). Record(s) in the contact list containing a nickname that exceeds a threshold degree of similarity as the keyword(s) are identified.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Abstract: Provided herein are improved processes for converting C7-amino-substituted tetracyclines to C7-fluoro-substituted tetracyclines, as well as intermediates produced by or used in these processes. In one embodiment, a thermal fluorination method is provided in which a suspension comprising a non-polar organic solvent and a C7-diazo-substituted tetracycline hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is heated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof. In another embodiment, a photolytic fluorination is provided in which a solution comprising an ionic liquid and a C7-diazo-substituted tetracycline tetrafluoroborate, hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is irradiated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Abstract: Provided herein are improved processes for converting C7-amino-substituted tetracyclines to C7-fluoro-substituted tetracyclines, as well as intermediates produced by or used in these processes. In one embodiment, a thermal fluorination method is provided in which a suspension comprising a non-polar organic solvent and a C7-diazo-substituted tetracycline hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is heated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof. In another embodiment, a photolytic fluorination is provided in which a solution comprising an ionic liquid and a C7-diazo-substituted tetracycline tetrafluoroborate, hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is irradiated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Abstract: Provided herein are improved processes for convening C7-amino-substituted tetracylines to C7-fluoro-substituted tetracyclines as well as intermediates produced by or used in these processes. In one embodiment, a thermal fluorination method is provided in which a suspension comprising a non-polar organic solvent and a C7-diazo-substituted tetracycline hexafluorophosphate, hexafluoarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is healed to provide a C7-fluoro-substituted tetracyline, or salt, solvate or combination thereof. In another embodiment, a photolytic fluorination is provided in which a solution comprising an ionic liquid and a C-7diazo-substituted tetracyline tetrafluoroborate, hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is irradiated to provide a C7-fluoro-substituted tetracyline, or salt, solvate or combination thereof.

Abstract: Provided herein are improved processes for convening C7-amino-substituted tetracylines to C7-fluoro-substituted tetracyclines as well as intermediates produced by or used in these processes. In one embodiment, a thermal fluorination method is provided in which a suspension comprising a non-polar organic solvent and a C7-diazo-substituted tetracycline hexafluorophosphate, hexafluoarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof is healed to provide a C7-fluoro-substituted tetracyline, or salt, solvate or combination thereof. In another embodiment, a photolytic fluorination is provided in which a solution comprising an ionic liquid and a C-7diazo-substituted tetracyline tetrafluoroborate, hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof is irradiated to provide a C7-fluoro-substituted tetracyline, or salt, solvate or combination thereof.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Abstract: An application store system and an application development method using the application store system are provided in the disclosure.